India, June 23 -- Belgium-based Quantoom (operating as Phoenix Biosciences SA) and Hyderabad-based Nucelion Therapeutics have announced the signing of a Memorandum of Understanding (MoU) to explore a preferred RNA contract development and manufacturing (CDMO) partnership in India.

Under the MoU, Nucelion would operate Quantoom's N-Force platform technologies to provide both research-grade and GMP-grade RNA manufacturing services to clients across human therapeutics and animal health.

The collaboration reflects a shared view of the significant and growing opportunity for RNA-based products in India and the broader Asia-Pacific region - spanning mRNA therapeutics, RNA-based vaccines, oligonucleotide therapies, and veterinary applications....